cetrorelix (cetrotide) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Cetrorelix is marketed primarily under the brand name Cetrotide. Cetrotide (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.   NCATS

Chemistry

  • SMILES: CC(C)C[C@H](NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc3ccc(Cl)cc3)NC(=O)[C@@H](Cc4ccc5ccccc5c4)NC(=O)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(=O)N
  • InChIKey: SBNPWPIBESPSIF-MHWMIDJBSA-N
  • Mol. Mass: 1431.06
  • ALogP: Missing data
  • ChEMBL Molecules:
    cetrorelix  
    cetrorelix acetate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

cetrorelix | cetrorelix acetate | cetrorelix pamoate | cetrorelixum | cetrotide | citrotide | d-20761 | lhrh, n-ac-1-nal(2)-2-phe(pcl)-3-pal(3)-6-cit-10-ala- | lhrh, n-acetyl-1-(3-(2-naphthyl)alanyl)-2-(4-chlorophenylalanyl)-3-(3-(3-pyridyl)alanyl)-6-citrulline-10-alanine- | n-acetyl-1-(3-(2-naphthyl)alanine)-2-(4-chlorophenylalanine)-3-(3-(3-pyridyl)alanine)-6-citrulline-10-alanine-lhrh | ns-75a | sb-075 acetate | sb 75 | sb-75

Organizations (75)

Research & Development (72)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (1)


 

Infertility, Female (approved 2000)

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Aging (Early Phase 1)

Arthritis, Rheumatoid (Phase 2)

Clomiphene (Phase 4)

Endometriosis (Phase 2)

Fertilization in Vitro (Phase 4)

Gonadotropin-Releasing Hormone (Phase 4)

Gonadotropins (Phase 3)

Heart Diseases (Phase 4)

Infertility (Phase 4)

Infertility, Female (Phase 3)

Leiomyoma (Phase 4)

Menopause (Early Phase 1)

Oocytes (Phase 3)

Ovarian Cysts (Phase 4)

Ovarian Diseases (Phase 4)

Ovarian Hyperstimulation Syndrome (Phase 4)

Pituitary Diseases (Phase 2/Phase 3)

Polycystic Ovary Syndrome (Phase 4)

Prostatic Hyperplasia (Phase 3)

Reproduction (Phase 2)

Reproductive Health (Phase 4)

Reproductive Techniques, Assisted (Phase 2)

Sperm Injections, Intracytoplasmic (Phase 4)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Ventricular Dysfunction, Left (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 73
  • # of Trial Organizations: 72

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue